Weekly diabetes treatment shows promise in international study

Credit: Unsplash+

A recent study presented at a substantial meeting of diabetes experts in San Diego has shed light on a new medication, icodec, potentially changing the game for people living with type 2 diabetes.

Dr. Ildiko Lingvay from a university in Dallas led the research, which spanned 11 countries and involved participation from 92 different locations.

The goal was to gauge the efficacy of icodec in comparison to another medication, degludec, both of which are variants of insulin.

Participants were segregated into two groups: one administering icodec weekly and the other utilizing degludec daily.

Findings: Analyzing the Efficacy of Icodec and Degludec

After a 26-week period, both medications demonstrated a capacity to lower blood sugar levels, measured by the HbA1c level.

For those taking icodec, HbA1c levels reduced from 8.6% to 7.0%, while the group utilizing degludec saw a decrease from 8.5% to 7.2%. Thus, icodec exhibited marginally superior efficacy.

However, when evaluating parameters such as morning sugar levels, medication dosage, and weight fluctuations, no significant disparities were observed between the two groups.

A concerning observation was the incidence of hypoglycemia (low blood sugar), which was more prevalent in the icodec group, especially during the initial 26 weeks of administration.

Implications for Patients and Healthcare Professionals

The study suggests that icodec, with its once-a-week administration, could be as effective as the daily-administered degludec.

This is potentially transformative for patients, as less frequent dosing can simplify management of the condition. However, it comes with the caveat of a slightly elevated risk of experiencing low blood sugar.

In interpreting the results, the authors underscored that healthcare professionals considering icodec should weigh the minor additional benefit and the convenience of the reduced dosing schedule against the slightly heightened risk of hypoglycemia.

A Caveat: Funding and Potential Biases in the Study

It is critical to note that Novo Nordisk, the pharmaceutical company that produces icodec, funded the study.

Furthermore, some participants in the study are employed by pharmaceutical companies, including Novo Nordisk, which necessitates a careful and critical interpretation of the findings.

Looking Forward and Additional Resources

For those keen on staying abreast of developments in diabetes research, it is advisable to delve into additional studies pertaining to potential cures for type 2 diabetes and exploring the socioeconomic and systemic issues impacting the accessibility and affordability of insulin for diabetes patients.

For broader health insights, examining recent research into how dietary components, like blueberries and eggs, might interact with metabolic syndrome and type 2 diabetes respectively, can provide a well-rounded perspective on managing and potentially mitigating the impact of metabolic disorders.

The study’s details and findings are available in JAMA for those interested in a deeper, scientific exploration of the research.

If you care about diabetes, please read studies about high vitamin D level linked to lower dementia risk in diabetes, and this eating habit could help reduce risk of type 2 diabetes.

For more information about nutrition, please see recent studies about unhealthy plant-based diets linked to metabolic syndrome, and results showing Paleo diet plus exercise could boost heart health in people with diabetes

Follow us on Twitter for more articles about this topic.

Copyright © 2023 Knowridge Science Report. All rights reserved.